SectorBiological Technology
Established Date13/11/2012
Listing Date12/06/2020
ExchangeNASDAQ Stock Exchange
Full-time Employees511
Fiscal Year Ends31/12
Security TypeCommon stock
Office address3020 Callan Road, San Diego, CA 92121
Business
IntroductionAvidity Biosciences, Inc., was incorporated on November 13, 2012 under the laws of the State of Delaware. The company is working on a new class of RNA therapies called antibody oligonucleotide conjugates (AOCs). Its proprietary AOC platform combines the specificity of monoclonal antibodies with the precision of RNA therapies to target previously incurable diseases. Avidity's pipeline includes three clinical development programs: delpacibart zotadirsen for Duchenne muscular dystrophy, delpacibart etedesiran for type 1 myotonic dystrophy, and delpacibart braxlosiran for facioscapulobrachial muscular dystrophy. All of these investigational therapies have received orphan designation and fast track status from regulatory agencies. In November 2025, Avidity announced its del-zota managed access program in the United States, providing access to eligible patients through an authorized treatment regimen.
